NEW YORK, NY / ACCESSWIRE / July 2, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of OncoCyte Corporation ("OncoCyte" or the "Company") (NYSE: OCX). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/ocx.
The investigation concerns whether OncoCyte and certain of its officers and/or directors have violated federal securities laws.
On June 26, 2019, OncoCyte issued a press release announcing that "the Company will require additional time to complete its ongoing CLIA Validation study of DetermaVu™, its liquid biopsy test for lung cancer." On this news, OncoCyte's stock price fell $1.47 per share, or 36.84%, to close at $2.52 per share on June 26, 2019.
If you are aware of any facts relating to this investigation, or purchased OncoCyte shares,you can assist this investigation by visiting the firm's site: www.bgandg.com/ocx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz and Grossman, LLC